Virus-Like Particles (VLPs)

Creative Biolabs is a world-renowned service provider for virus-like particles (VLPs) technology. Notably, several VLP-derived vaccine candidates have been successfully obtained by our cutting-edge VLPs technique platform. Our seasoned scientists are pleased to offer the best service and the most qualified products to serve every specific demand from our customers all over the world.

Virus-like particles (VLPs) are artificial protein structures with the similar overall structure to their corresponding native viruses. They resemble viruses with self-assembly property but losing original infectious ability due to the genome modifications. VLPs are symmetrically built from hundreds of coat proteins, which can be genetically engineered to present a regular arrangement of epitope chains on the desired positions of the outer surface. Compared with monomeric or oligomeric protein carriers, VLPs are able to provide not only a higher density of foreign proteins per particle but also support a distinctive three-dimensional conformation, which is especially important for the presentation of conformational epitopes. Currently, VLPs has been recognized as one of the most promising and extensively studied molecular carriers or nanoparticles, for a variety of applications.

Since the 1980s, over 100 VLPs originated from microbial, insect, plant and mammalian viruses have been constructed and characterized. Creative Biolabs provides high-quality VLPs products derived from various virus families including HBV VLP, HIV VLP, HPV VLP, CA16 VLP, EV71 VLP, poliovirus VLP, MERS-CoV VLP, SARS-CoV VLP, SARS-CoV-2 VLP, polyomaviruses VLP, AAV VLP, bacteriophage Qβ VLP, Zika VLP, etc.

One crucial step for successful VLPs production lies in the proper choice of appropriate expression host system. In general, selection of an ideal system depends on many factors, e.g. the specific target, desired quantity, downstream applications, etc. Creative Biolabs has established a broad range of well-established expression platforms, which can meet diverse research and industrial objectives:

Virus-Like Particles (VLPs)

In fact, some vaccines derived from VLPs have been used as medical products commercially, and other VLP-based products are already at different stages of the clinical study. Several remarkable advantages have been achieved in the development of VLPs as gene therapy tools and new delivery nanomaterials. Generally speaking, VLPs have great potential for a number of applications including:

Vaccine development: Our team has vast experience in designing and developing VLP products to deliver integral antigens with both arms of the adaptive immunity. Our VLPs-based vaccine formulation is able to enhance the antigen immunogenicity remarkably by using adjuvant aluminum salts. Moreover, special methods will be employed to reduce preservative and VLPs aggregation.

Antibody development: VLPs can serve as a perfect immunogen which can elicit highly potent immune responses in vivo. We have successfully raised many antibody binders using VLP immunization strategy, particularly against viral antigens or membrane antigens.

Lipoparticle technology: Our team now provides highly purified and stable VLPs containing a great variety of membrane proteins in the form of lipoparticles to satisfying different demands such as ligand binding assays, antibody screening, and immunogen production.

Delivery systems: Our team is able to apply VLPs as delivery systems to transport various compounds including DNA, siRNA, peptide, protein, and drugs.

Bioimaging: Our team is professional in providing VLPs chemical modification services such as probe conjugation for bioimaging application both in vivo and in vitro in virtue of VLPs' high biological compatibility.

Cell targeting: We can develop sophisticated VLPs to enable highly specific cell targeting. Alternative approaches are available including vitamins, peptides, nucleic acids (aptamers), and carbohydrates proteins (mainly antibodies).

Creative Biolabs now offers state-of-the-art virus-like particles (VLPs) service based on our unparalleled technology platform. Our R&D team is made up of a group of self-inspired and experienced scientists, who are constantly devoted to providing the most professional and satisfactory assistance to our global customers. Please feel free to inquire us for further discussions.


  1. Shirbaghaee, Z., & Bolhassani, A. (2016). Different applications of virus‐like particles in biology and medicine: Vaccination and delivery systems. Biopolymers, 105(3), 113-132.
  2. Kaczmarczyk S J, Sitaraman K, Young H A, et al. (2011). Protein delivery using engineered virus-like particles. Proceedings of the National Academy of Sciences, 108(41), 16998-17003.
  3. Josefsberg J O, Buckland B. (2012). Vaccine process technology. Biotechnology and bioengineering, 109(6), 1443-1460.
  4. Lua L H L, Connors N K, Sainsbury F, et al. (2014). Bioengineering virus‐like particles as vaccines. Biotechnology and bioengineering, 111(3), 425-440.
  5. Chen Q, Lai H. Plant-derived virus-like particles as vaccines (2013). Plant-derived virus-like particles as vaccines. Human vaccines & immunotherapeutics, 9(1), 26-49.
  6. Yao L, Wang S, Su S, et al. (2012). Construction of a baculovirus-silkworm multigene expression system and its application on producing virus-like particles. PloS one, 7(3), e32510.
  7. Zeltins, A. (2013). Construction and characterization of virus-like particles: a review. Molecular biotechnology, 53(1), 92-107.
  8. Kushnir N, Streatfield S J, Yusibov V. (2012). Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine, 31(1), 58-83.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry


Call us at:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us